At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $916M, above the global median of $566.17M
- FinancialsAltman Z-Score 2.89: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.22%Above 5Y avg (3.48%)
Annual Rate
MXN 0.80Paid quarterly
Payout Ratio
45.8%Sustainable
Payback Period
19.8 yr
Last Ex-Dividend
Sep 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.99BMXN802.81M · vs all stocks (USD)
Trailing P/E
8.77xRevenue (TTM)
17.10BMXN916.00M · vs all stocks (USD)
Profit Margin
10.00%52-Week Change
-17.51%vs all stocks
Forward Annual Dividend Yield
5.22%vs all stocks
Market Capitalization
14.99BMXN802.81M · vs all stocks (USD)
Enterprise Value
19.87BMXN1.06B · vs all stocks (USD)
Trailing P/E
8.77xForward P/E
7.73xPEG Ratio
1.73xPrice to Sales (TTM)
0.8724xPrice to Book (MRQ)
1.84xEnterprise to Revenue
1.16xEnterprise to EBITDA
5.25xGross Margin
64.56%Profit Margin
10.00%Operating Margin
19.20%Return on Assets (TTM)
8.74%Return on Equity (TTM)
14.72%Revenue (TTM)
17.10BMXN916.00M · vs all stocks (USD)
Revenue per Share (TTM)
12.79MXNUpdated Oct 25, 2026Quarterly Revenue Growth
1.30%Gross Profit (TTM)
10.71BMXN573.50M · vs all stocks (USD)
EBITDA (TTM)
3.86BMXN206.79M · vs all stocks (USD)
Net Income (TTM)
1.71BMXN91.60M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.60%Operating Cash Flow (TTM)
1.91BMXN102.05M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
4.37BMXN233.92M · vs all stocks (USD)
Forward Annual Dividend Rate
0.8000MXNUpdated Oct 25, 2026Forward Annual Dividend Yield
5.22%vs all stocks
Trailing Annual Dividend Rate
0.8000MXNUpdated Oct 25, 2026Trailing Annual Dividend Yield
5.22%vs all stocks
5-Year Average Dividend Yield
3.48%vs all stocks
Payout Ratio
45.75%Revenue
17.54BMXNFY2025 · Dec 31, 2025Cost of Goods Sold
6.52BMXNFY2025 · Dec 31, 2025Gross Profit
11.02BMXNFY2025 · Dec 31, 2025Operating Income
3.76BMXN201.19M · vs all stocks (USD)
Pre-tax Income
2.43BMXNFY2025 · Dec 31, 2025Income Tax Expense
819.75MMXNFY2025 · Dec 31, 2025Net Income
1.61BMXNFY2025 · Dec 31, 2025EBIT
3.23BMXNFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.86BMXNFY2025 · Dec 31, 2025Selling, General & Administrative
7.29BMXNFY2025 · Dec 31, 2025Other Operating Expenses
-26.24MMXNFY2025 · Dec 31, 2025Non-operating Interest Income
114.02MMXNFY2025 · Dec 31, 2025Non-operating Interest Expense
796.70MMXNFY2025 · Dec 31, 2025EPS (Basic)
1.64MXNFY2025 · Dec 31, 2025EPS (Diluted)
1.64MXNFY2025 · Dec 31, 2025Basic Shares Outstanding
977.75MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
977.75MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.61BMXNFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00MXNFY2025 · Dec 31, 2025Operating Cash Flow
1.75BMXNFY2025 · Dec 31, 2025Free Cash Flow
1.74BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.05BMXNFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.61BMXNFY2025 · Dec 31, 2025Other Non-cash Items
942.80MMXNFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-602.36MMXNFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-196.24MMXNFY2025 · Dec 31, 2025Capital Expenditures
10.80MMXNFY2025 · Dec 31, 2025Purchase of Investments
-34.27MMXNFY2025 · Dec 31, 2025Other Investing Activity
-170.88MMXNFY2025 · Dec 31, 2025Net Investing Cash Flow
-194.35MMXNFY2025 · Dec 31, 2025Long-term Debt Issuance
5.03BMXNFY2025 · Dec 31, 2025Long-term Debt Payments
-3.83BMXNFY2025 · Dec 31, 2025Common Dividends Paid
-781.77MMXNFY2025 · Dec 31, 2025Net Financing Cash Flow
419.21MMXNFY2025 · Dec 31, 2025Shares Outstanding
977.75MSharesUpdated Oct 25, 2026% Held by Insiders
31.05%vs all stocks
% Held by Institutions
32.18%vs all stocks
Total Cash (MRQ)
2.74BMXN146.61M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.86MXNUpdated Oct 25, 2026Total Debt (MRQ)
58.22MMXN3.12M · vs all stocks (USD)
Current Ratio (MRQ)
1.75xBook Value per Share (MRQ)
8.32MXNUpdated Oct 25, 2026Total Assets
23.83BMXN1.28B · vs all stocks (USD)
Total Current Assets
12.84BMXNFY2025 · Dec 31, 2025Total Liabilities
12.72BMXNFY2025 · Dec 31, 2025Total Non-current Assets
11.00BMXNFY2025 · Dec 31, 2025Total Non-current Liabilities
5.49BMXNFY2025 · Dec 31, 2025Total Current Liabilities
7.23BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.07BMXNFY2025 · Dec 31, 2025Accounts Receivable
4.50BMXNFY2025 · Dec 31, 2025Inventory
1.84BMXNFY2025 · Dec 31, 2025Accounts Payable
1.58BMXNFY2025 · Dec 31, 2025Short-term Debt
2.80BMXNFY2025 · Dec 31, 2025Other Current Liabilities
2.60BMXNFY2025 · Dec 31, 2025Long-term Debt
4.77BMXNFY2025 · Dec 31, 2025Other Non-current Liabilities
720.36MMXNFY2025 · Dec 31, 2025Common Stock (Book)
1.83BMXNFY2025 · Dec 31, 2025Retained Earnings
12.22BMXNFY2025 · Dec 31, 2025Total Shareholders' Equity
11.11BMXN595.13M · vs all stocks (USD)
Treasury Stock
1.85BMXNFY2025 · Dec 31, 202552-Week Low
12.22MXNUpdated Oct 25, 202652-Week High
19.48MXNUpdated Oct 25, 202652-Week Change
-17.51%vs all stocks
50-Day MA
13.21MXNUpdated Oct 25, 2026200-Day MA
15.60MXNUpdated Oct 25, 2026Avg 10-Day Volume
4.20MSharesUpdated Oct 25, 2026Avg 30-Day Volume
3.98MSharesUpdated Oct 25, 2026Diluted EPS (TTM)
1.74MXNUpdated Oct 25, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.89: safe zoneNotable
Altman Z-Score: 2.89
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $916M, above the global median of $566.17MNotable
Revenue (USD): 915,997,057.597Global Median: 566,172,992
Levered free cash flow is $233.92M, above the global median of $18.58MNotable
Levered free cash flow (USD): 233,919,915.008Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule